acalabrutinib + obinutuzumab + venetoclax

The combination of **acalabrutinib + obinutuzumab + venetoclax** is an investigational regimen combining three agents for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)[1][3][4][5]. - **Acalabrutinib** is a second-generation small molecule inhibitor of Bruton's tyrosine kinase (BTK), which disrupts B-cell receptor signaling, inhibiting malignant B-cell growth and survival. - **Obinutuzumab** is a glycoengineered type II anti-CD20 monoclonal antibody that targets CD20 on B cells, mediating direct cell death and antibody-dependent cellular cytotoxicity. - **Venetoclax** is a selective inhibitor of the anti-apoptotic protein BCL2, inducing apoptosis specifically in B-cell malignancies. The combination is intended to achieve deep and durable remissions (including undetectable minimal residual disease, uMRD) by synergistically combining BCR signaling inhibition, immune-mediated cytotoxicity, and apoptosis induction. This regimen is being studied in both relapsed/refractory and treatment-naive CLL patients[1][3][4][5]. It is not approved by major regulatory bodies for routine clinical use as a triple regimen, but individual agents and doublets have received approvals.

Other names

CalquenceGazyvaroVenclyxto